Virginia Retirement Systems ET AL purchased a new stake in Shattuck Labs, Inc. (NASDAQ:STTK – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,400 shares of the company’s stock, valued at approximately $140,000.
Several other large investors have also recently made changes to their positions in STTK. Investment Management of Virginia LLC increased its position in Shattuck Labs by 395.6% in the 4th quarter. Investment Management of Virginia LLC now owns 181,656 shares of the company’s stock valued at $1,545,000 after acquiring an additional 145,000 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Shattuck Labs by 64.1% during the third quarter. Victory Capital Management Inc. now owns 148,140 shares of the company’s stock valued at $3,019,000 after purchasing an additional 57,840 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Shattuck Labs by 96.1% during the third quarter. Ensign Peak Advisors Inc now owns 58,822 shares of the company’s stock valued at $1,199,000 after purchasing an additional 28,822 shares in the last quarter. EcoR1 Capital LLC lifted its holdings in Shattuck Labs by 11.8% in the third quarter. EcoR1 Capital LLC now owns 3,709,072 shares of the company’s stock worth $75,591,000 after purchasing an additional 390,662 shares during the period. Finally, Prosight Management LP bought a new position in Shattuck Labs in the 3rd quarter valued at about $3,449,000. Institutional investors own 66.62% of the company’s stock.
Shares of Shattuck Labs stock opened at $3.90 on Friday. Shattuck Labs, Inc. has a 52 week low of $3.35 and a 52 week high of $38.90. The stock has a market cap of $164.76 million, a PE ratio of -3.64 and a beta of 3.30. The company’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $8.69.
A number of analysts have commented on STTK shares. Needham & Company LLC dropped their price target on shares of Shattuck Labs from $46.00 to $31.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th. Zacks Investment Research upgraded Shattuck Labs from a “sell” rating to a “hold” rating in a research report on Wednesday, January 12th.
About Shattuck Labs (Get Rating)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
- Get a free copy of the StockNews.com research report on Shattuck Labs (STTK)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.